TEVA-Teva Announces Strong Financial Results for the Third Quarter of 2024, led by Generics Performance and Innovative Portfolio Growth; Raises 2024 Financial Outlook including on Revenues, Adjusted EBITDA and Non-GAAP EPS

For an accessible version of this Press Release, please visit www.tevapharm.com Q3 2024 revenues of $4.3 billion reflect an increase of 13% in U.S. dollars, or 15% in local currency terms, compared to Q3 2023.AUSTEDO® – shows continued growth, U.S. revenues of$ 435 million in Q3 2024, an increase of 28% compared to Q3 2023; reaffirming 2024 revenue outlook of ~ $1.6 billion.AJOVY® – global revenues of$ 137 million in Q3 2024, an increase of 21% in local currency terms compared to Q3 2023.UZEDY® is gaining mo ...